...
首页> 外文期刊>Cardiovascular therapeutics >Effect of seven different modalities of antihypertensive therapy on pulse pressure in patients with newly diagnosed stage I hypertension.
【24h】

Effect of seven different modalities of antihypertensive therapy on pulse pressure in patients with newly diagnosed stage I hypertension.

机译:七种不同形式的降压治疗对初诊I期高血压患者脉压的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

In this study, we investigated the effect of different antihypertensive agents on pulse pressure (PP). The study was designed in a prospective manner and patients were sequentially allocated to one of the seven different therapy groups, according to the order of enrollment (every first patient to group I, every second patient to group II, and etc). Patients in group I received 10 mg of lisinopril, in group II 10/6.25 mg of lisinopril/hydrochlorothiazide, in group III 80 mg of valsartan, in group IV 80/6.25 mg of valsartan/hydrochlorothiazide, in group V 5 mg of amlodipine, in group VI 1.25 mg of indapamide, and finally those in group VII received 50 mg of atenolol. The reduction in PP was more significant in patients receiving lisinopril, lisinopril hydrochlorothiazide, valsartan, and valsartan hydrochlorothiazide, when compared with patients receiving indapamide, atenolol, and amlodipine (P < 0.05 for each group). Factors such as age, gender, and body mass index were not found to significantly influence the effectiveness of antihypertensive agents on PP. The reduction in PP was more apparent with lisinopril, lisinopril hydrochlorothiazide, valsartan, and valsartan hydrochlorothiazide in diabetic patients, when compared with those without diabetes (P < 0.001, P < 0.05). And also patients on therapy with 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors had a greater reduction in PP with lisinopril, lisinopril hydrochlorothiazide, valsartan, and valsartan hydrochlorothiazide (P < 0.001, P < 0.05).
机译:在这项研究中,我们调查了不同的降压药对脉压(PP)的影响。该研究以前瞻性方式设计,并且根据入选顺序(将每个第一位患者分组为I,将每个第二位患者分组为II,依此类推)将患者依次分配到七个不同的治疗组之一。 I组患者接受10 mg赖诺普利,II组患者接受10 / 6.25 mg赖诺普利/氢氯噻嗪,III组患者接受80 mg缬沙坦,IV组患者接受80 / 6.25 mg缬沙坦/氢氯噻嗪,V组接受5 mg氨氯地平,在VI组中,1.25毫克吲达帕胺,最后在VII组中,接受50毫克阿替洛尔。与接受吲达帕胺,阿替洛尔和氨氯地平的患者相比,接受赖诺普利,赖诺普利氢氯噻嗪,缬沙坦和缬沙坦氢氯噻嗪的患者PP的降低更为显着(每组P <0.05)。未发现年龄,性别和体重指数等因素显着影响降压药对PP的有效性。与没有糖尿病的患者相比,赖诺普利,赖诺普利氢氯噻嗪,缬沙坦和缬沙坦氢氯噻嗪对PP的降低更为明显(P <0.001,P <0.05)。此外,接受3-羟基-3-甲基-戊二酰辅酶A(HMG-CoA)还原酶抑制剂治疗的患者,赖诺普利,赖诺普利氢氯噻嗪,缬沙坦和缬沙坦氢氯噻嗪的PP降低更大(P <0.001,P <0.05) 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号